公开(公告)号：WO2022140290A1

公开(公告)日：2022-06-30

申请号：PCT/US2021/064422

申请日：2021-12-20

申请人： CYTOKINETICS, INC.

发明人： SHEN, Minxing ,  ROMERO, Antonio ,  LU, Pu-Ping

IPC分类号： C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  A61P35/00 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/10 ,  A61K31/506

摘要： Provided herein are compounds of formula (A): or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, Ry, and Rz are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (A), or a pharmaceutically acceptable salt thereof, as well as methods of using a compound of formula (A), or a pharmaceutically acceptable salt thereof, to treat various diseases and conditions mediated by nicotinamide phosphoribosyltransferase (NAMPT).

公开(公告)号：WO2021226276A2

公开(公告)日：2021-11-11

申请号：PCT/US2021/030950

申请日：2021-05-05

申请人： CYTOKINETICS, INC.

发明人： ROMERO, Antonio ,  CHANDRA, Aroop ,  EVANS, Christopher ,  SHEN, Minxing

IPC分类号： C07D401/12 ,  C07D213/40 ,  C07D211/98 ,  C07D231/12 ,  C07D263/32 ,  C07D413/12 ,  C07D221/20 ,  C07D213/38 ,  C07D205/12 ,  C07D207/06 ,  C07D205/04 ,  C07D401/04 ,  C07D295/192 ,  C07D215/08 ,  C07D217/06 ,  A61P25/00 ,  A61P29/00 ,  A61P3/00 ,  A61P35/00 ,  C07B2200/07 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/24 ,  C07C2602/28 ,  C07C2603/94 ,  C07C275/24 ,  C07C275/26 ,  C07C317/28 ,  C07C317/30 ,  C07D209/08 ,  C07D209/44 ,  C07D209/54 ,  C07D211/94 ,  C07D213/50 ,  C07D213/71 ,  C07D213/81 ,  C07D213/82 ,  C07D215/12 ,  C07D215/18 ,  C07D215/20 ,  C07D231/56 ,  C07D241/04 ,  C07D265/36 ,  C07D295/185 ,  C07D305/08 ,  C07D307/22 ,  C07D309/08 ,  C07D335/02 ,  C07D401/06 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D413/06 ,  C07D471/04

摘要： Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2021159015A1

公开(公告)日：2021-08-12

申请号：PCT/US2021/016948

申请日：2021-02-05

申请人： CYTOKINETICS, INC.

发明人： ROMERO, Antonio ,  CHANDRA, Aroop ,  EVANS, Christopher Edward ,  SHEN, Minxing

IPC分类号： C07D213/36 ,  C07C275/28 ,  A61P3/00 ,  A61P25/16 ,  A61P29/00 ,  A61P35/00 ,  C07D205/04 ,  C07D207/16 ,  C07D213/81 ,  C07D241/12 ,  C07D295/073 ,  C07D305/08 ,  C07D309/14 ,  C07D331/04 ,  C07D333/08 ,  C07D335/02 ,  C07D491/22 ,  A61K31/17 ,  A61K31/4422

摘要： Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.